Estonia to develop personalized CAR T-cell therapy for blood cancer patients

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

A new study details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the clinical-stage cell therapy company Vittoria Biotherapeutics’ proprietary Senza5TM platform.

July 26, 2024

Vol.50 No.30

Health Equity White House

Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa

Source: Livestream of White House Africa Cancer Care ForumThe White House Cancer Moonshot is committing an additional $100 million to programs focused on reducing cancer burden in African countries.

July 19, 2024

Vol.50 No.29

By McKenzie Prillaman

Clinical Roundup

Cell donor’s socioeconomic status shapes cancer treatment outcomes

The socioeconomic status of cell donors affects the health outcomes of blood cancer patients who underwent hematopoietic cell transplantation, according to a new study led by researchers at the University of Minnesota Medical School.

July 19, 2024

Vol.50 No.29

Conversation with The Cancer Letter

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.

July 12, 2024

Vol.50 No.28

By Matthew Bin Han Ong

Drugs & Targets

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

Patients treated with CAR T-cell medicines should be monitored life-long for secondary malignancies.

June 21, 2024

Vol.50 No.25

Clinical Roundup

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

A pioneering phase I CAR T-cell therapy trial for the treatment of glioblastoma at City of Hope, demonstrates promising clinical activity against incurable brain tumors, according to research published in Nature Medicine.

June 14, 2024

Vol.50 No.24

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

YOU MAY BE INTERESTED IN

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa

Cell donor’s socioeconomic status shapes cancer treatment outcomes

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

Renew today!

Subscriber content

Login

Estonia to develop personalized CAR T-cell therapy for blood cancer patients

YOU MAY BE INTERESTED IN

CD5 deletion enhances the antitumor activity of adoptive T-cell therapies

Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa

Cell donor’s socioeconomic status shapes cancer treatment outcomes

Infections are a major cause of death in patients treated with CAR T-cell therapyMeta-analysis focused on causes of death, excluding relapse, recurrence

EMA PRAC identifies risk of secondary malignancies from CAR T-cell medicines

CAR T-cell therapy delivered to the brain shows clinical activity in glioblastoma in phase I study

Login

Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence